Enhanced self-renewal of human long-term hematopoietic stem cells by a sulfamoyl benzoate derivative targeting p18INK4C
Yinghui Li,Wenshan Zhang,Yu Zhang,Yahui Ding,Ming Yang,Mei He,Xiaolei Liu,Jiali Gu,Shiqi Xu,Zhiwei Feng,Yafang Li,Jingjing Yin,Huier Gao,Henan Song,Hui Xu,Chaoqun Wang,Qing Ji,Shihui Ma,Wanzhu Yang,Weiping Yuan,Xiang-Qun Xie,Tao Cheng,Yingdai Gao
DOI: https://doi.org/10.1182/bloodadvances.2020004054
IF: 7.642
2021-09-03
Blood Advances
Abstract:Abstract The use of umbilical cord blood transplant has been substantially limited by the finite number of hematopoietic stem and progenitor cells in a single umbilical cord blood unit. Small molecules that not only quantitatively but also qualitatively stimulate enhancement of hematopoietic stem cell (HSC) self-renewal ex vivo should facilitate the clinical use of HSC transplantation and gene therapy. Recent evidence has suggested that the cyclin-dependent kinase inhibitor, p18INK4C (p18), is a critical regulator of mice HSC self-renewal. The role of p18 in human HSCs and the effect of p18 inhibitor on human HSC expansion ex vivo need further studies. Here we report that knockdown of p18 allowed for an increase in long-term colony-forming cells in vitro. We then identified an optimized small molecule inhibitor of p18, 005A, to induce ex vivo expansion of HSCs that was capable of reconstituting human hematopoiesis for at least 4 months in immunocompromised mice, and hence, similarly reconstituted secondary recipients for at least 4 more months, indicating that cells exposed to 005A were still competent in secondary recipients. Mechanistic studies showed that 005A might delay cell division and activate both the Notch signaling pathway and expression of transcription factor HoxB4, leading to enhancement of the self-renewal of long-term engrafting HSCs and the pool of progenitor cells. Taken together, these observations support a role for p18 in human HSC maintenance and that the p18 inhibitor 005A can enhance the self-renewal of long-term HSCs.
hematology